GLP-1 Picks and Shovels
l@sasacul123
−0.5%
since Oct 7
The idea
I think GLP-1 drugs keep scaling for a decade no matter which company's version wins, so instead of betting on a drugmaker I own what every format needs to get made: injection hardware like auto-injector parts and pen needles, the purification and process tools behind both pills and shots, the plant builders expanding capacity, and distributors who earn on volume either way. I spread across injectable and oral delivery rather than picking one, keep no single company too large, hold a cash cushion, and plan to hold for years unless the basic thesis that GLP-1 demand keeps growing breaks down.
What it owns
- Injectable GLP-1s require syringes, stoppers, needles and glass from a concentrated group of suppliers, so volume growth flows directly to their revenue. · West Pharmaceutical ServicesIt supplies the stoppers, seals and auto-injector components that go into every injectable GLP-1 dose, capturing volume revenue across all makers., Stevanato GroupIt manufactures the syringe barrels and cartridge glass that form the foundation of injectable pens, positioned upstream of the prescription., Becton DickinsonIt manufactures pen needles at unmatched scale, so rising GLP-1 injections mean proportionally higher needle consumption., AptarGroupIt supplies drug delivery components and elastomer parts for injectable systems, with revenue tied directly to total dose volume., CorningIts pharma glass vials form part of the injectable supply chain, with growth tied to GLP-1 fill-finish volume.28%
- Every GLP-1 dose passes through the same purification, filtration and quality-control equipment regardless of format or maker. · DanaherIt sells the bioprocessing and filtration equipment that sits inside every GLP-1 production line, earning on manufacturing scale regardless of drug format., RepligenIt makes the purification systems that peptide drugs like GLP-1s must pass through before shipment, with demand tied to total output growth., Agilent TechnologiesIts analytical lab instruments sit in the testing facilities of every company making or manufacturing these drugs, another toll on batch volume., WatersIt supplies the quality-control instruments that test every batch of GLP-1 drug before release, with consumables revenue tied to production volume., AvantorIt supplies the production chemicals and lab materials consumed with each batch made, generating recurring revenue from volume rather than customer concentration., VeraltoIts coding and inspection systems mark and verify every unit leaving a GLP-1 plant, earning on total shipped volume across formats.27%
- Drugmakers are spending tens of billions on new fill-finish and pill plants, and the builders and operators of that capacity will earn throughout the construction cycle. · Thermo Fisher ScientificIt operates contract manufacturing lines for injectable fill-finish and oral pill capacity, earning on every dose outsourced rather than made in-house., EMCOR GroupIt builds the cleanrooms and pharma manufacturing facilities required for new GLP-1 capacity, earning as long as the construction boom continues., FluorIt undertakes the largest pharma construction projects when drugmakers commit billions to new GLP-1 capacity.18%
- Drug distributors earn a toll on every prescription moved, so they benefit from GLP-1 volume growth independent of which format or company gains share. · McKessonIt moves prescriptions from manufacturer to pharmacy and clips a fee on each one, earning on volume independent of which company makes the drug., CencoraIt is a major distribution channel for GLP-1 scripts, positioned to benefit from a decade of rising prescription volumes., Cardinal HealthIt distributes prescriptions through the pharmacy channel and earns on script volume regardless of drug format or maker.17%
- Cash10%